Ferric Derisomaltose — Active Pharmaceutical Ingredient

Ferric Derisomaltose is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: SOLUTION. Routes: INTRAVENOUS.

This content is for informational purposes only. Always consult a healthcare professional.

Ferric Derisomaltose (1 brand name, 1 dosage form, 1 route)

Available dosage forms: SOLUTION.

Routes of administration: INTRAVENOUS.

Brand Names

  • MONOFERRIC

Indications and Usage

Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)

Contraindications

Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components (see Warnings and Precautions (5.1), Description (11)) . Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

Adverse Reactions

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity Reactions (see Warnings and Precautions (5.1)) . Iron Overload (see Warnings and Precautions (5.2)) .

Mechanism of Action

Ferric derisomaltose is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.

Overdosage

Excessive dosages of Monoferric may lead to accumulation of iron in storage sites potentially leading to hemosiderosis and hemochromatosis. Avoid use of Monoferric in patients with iron overload (see Warnings and Precautions (5.2)) .

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.